Protalix BioTherapeutics Inc (PLX):企業の財務・戦略的SWOT分析

◆英語タイトル:Protalix BioTherapeutics Inc (PLX) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH81688FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年4月
◆ページ数:50
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イスラエル
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD250 ⇒換算¥27,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥40,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Protalix BioTherapeutics Inc (PLX) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Protalix BioTherapeutics Inc (Protalix) is a biopharmaceutical company that is involved in the development and commercialization of recombinant therapeutic proteins. The company’s marketed product, Elelyso (taliglucerase alfa), is an enzyme replacement therapy (ERT) for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease. The company also has pipeline product candidates that are intended for the treatment of Fabry disease, cystic fibrosis and NETs related diseases. The company develops its proprietary pipeline of recombinant therapeutic proteins through its proprietary technology, ProCellEx plant cell-based protein expression system. It allows the company to rapidly develop a protein for clinical testing, compared to other protein platforms. Protalix is headquartered in Carmiel, Israel.

Protalix BioTherapeutics Inc Key Recent Developments

Mar 30,2021: Protalix BioTherapeutics Reports Fiscal Year 2020 Financial and Business Results
Mar 22,2021: Protalix BioTherapeutics to Hold Fiscal Year 2020 Financial and Business Results Conference Call on March 30, 2021
Dec 30,2020: Protalix BioTherapeutics issues 2020 letter to shareholders
Oct 29,2020: Protalix BioTherapeutics reports third quarter 2020 financial results and provides business update
Oct 29,2020: Protalix BioTherapeutics to Reschedule Third Quarter 2020 Financial Results and Business Update Call for Friday, October 30

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Protalix BioTherapeutics Inc – Key Facts
Protalix BioTherapeutics Inc – Key Employees
Protalix BioTherapeutics Inc – Key Employee Biographies
Protalix BioTherapeutics Inc – Major Products and Services
Protalix BioTherapeutics Inc – History
Protalix BioTherapeutics Inc – Company Statement
Protalix BioTherapeutics Inc – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Protalix BioTherapeutics Inc – Business Description
R&D Overview
Protalix BioTherapeutics Inc – Corporate Strategy
Protalix BioTherapeutics Inc – SWOT Analysis
SWOT Analysis – Overview
Protalix BioTherapeutics Inc – Strengths
Protalix BioTherapeutics Inc – Weaknesses
Protalix BioTherapeutics Inc – Opportunities
Protalix BioTherapeutics Inc – Threats
Protalix BioTherapeutics Inc – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Protalix BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Protalix BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Protalix BioTherapeutics Inc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Mar 30, 2021: Protalix BioTherapeutics Reports Fiscal Year 2020 Financial and Business Results
Mar 22, 2021: Protalix BioTherapeutics to Hold Fiscal Year 2020 Financial and Business Results Conference Call on March 30, 2021
Dec 30, 2020: Protalix BioTherapeutics issues 2020 letter to shareholders
Oct 29, 2020: Protalix BioTherapeutics reports third quarter 2020 financial results and provides business update
Oct 29, 2020: Protalix BioTherapeutics to Reschedule Third Quarter 2020 Financial Results and Business Update Call for Friday, October 30
Sep 08, 2020: Protalix BioTherapeutics regains compliance with NYSE American Continued Listing Standards
Aug 10, 2020: Protalix BioTherapeutics reports second quarter 2020 financial results and provides business update
Jun 08, 2020: Protalix BioTherapeutics appoints Yael Hayon, Ph.D. as its new Vice President, Research and Development
Jun 01, 2020: Protalix BioTherapeutics reports first quarter 2020 financial results and business update
Mar 16, 2020: Protalix Biotherapeutics announces feasibility study with Kirin Holdings on the production of a novel complex protein
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Protalix BioTherapeutics Inc, Key Facts
Protalix BioTherapeutics Inc, Key Employees
Protalix BioTherapeutics Inc, Key Employee Biographies
Protalix BioTherapeutics Inc, Major Products and Services
Protalix BioTherapeutics Inc, History
Protalix BioTherapeutics Inc, Subsidiaries
Protalix BioTherapeutics Inc, Key Competitors
Protalix BioTherapeutics Inc, Ratios based on current share price
Protalix BioTherapeutics Inc, Annual Ratios
Protalix BioTherapeutics Inc, Annual Ratios (Cont...1)
Protalix BioTherapeutics Inc, Interim Ratios
Protalix BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Protalix BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Protalix BioTherapeutics Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[Protalix BioTherapeutics Inc (PLX):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Jyoti Structures Ltd (JYOTISTRUC):企業の財務・戦略的SWOT分析
    Jyoti Structures Ltd (JYOTISTRUC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • SteadyMed Therapeutics Inc:医療機器:M&Aディール及び事業提携情報
    Summary SteadyMed Therapeutics Inc (SteadyMed), a subsidiary of SteadyMed Ltd is a pharmaceutical company that develops and commercializes therapeutic product candidates. The company provides patchpump, a customizable, pre-filled, and pre-programmed disposable parenteral delivery platform for large …
  • Arthur J. Gallagher & Co:戦略・SWOT・企業財務分析
    Arthur J. Gallagher & Co - Strategy, SWOT and Corporate Finance Report Summary Arthur J. Gallagher & Co - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Accenture Plc (ACN):企業の財務・戦略的SWOT分析
    Accenture Plc (ACN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Kingspan Group Plc:企業の戦略・SWOT・財務情報
    Kingspan Group Plc - Strategy, SWOT and Corporate Finance Report Summary Kingspan Group Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Banque Cramer & Cie SA:企業の戦略・SWOT・財務情報
    Banque Cramer & Cie SA - Strategy, SWOT and Corporate Finance Report Summary Banque Cramer & Cie SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Profire Energy Inc (PFIE):企業の財務・戦略的SWOT分析
    Summary Profire Energy Inc (Profire Energy) is an oilfield technology company that undertakes design, development, and installation of combustion management technology and chemical injection solutions. The company offers products such as burner management systems and chemical management systems. Its …
  • Specialist Computer Centres Plc:企業の戦略・SWOT・財務情報
    Specialist Computer Centres Plc - Strategy, SWOT and Corporate Finance Report Summary Specialist Computer Centres Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • MorphoSys AG (MOR)-製薬・医療分野:企業M&A・提携分析
    Summary MorphoSys AG (Morphosys) is a developer of monoclonal antibodies for therapeutic, diagnostic and research applications. The company’s pipeline product include MOR208, MOR202, MOR103, MOR209/ES414, MOR106, and MOR107, among others. It drugs are used in the treatment of different types of canc …
  • Lazard Ltd:企業の戦略・SWOT・財務分析
    Lazard Ltd - Strategy, SWOT and Corporate Finance Report Summary Lazard Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Showa Shell Sekiyu K.K.:企業の戦略・SWOT・財務情報
    Showa Shell Sekiyu K.K. - Strategy, SWOT and Corporate Finance Report Summary Showa Shell Sekiyu K.K. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Makita Corporation (6586):企業の財務・戦略的SWOT分析
    Makita Corporation (6586) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • EVN AG:発電所・企業SWOT分析
    EVN AG - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees (executives) …
  • The Hain Celestial Group Inc (HAIN):企業の財務・戦略的SWOT分析
    The Hain Celestial Group Inc (HAIN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Dundee Precious Metals Inc.:企業の戦略・SWOT・財務情報
    Dundee Precious Metals Inc. - Strategy, SWOT and Corporate Finance Report Summary Dundee Precious Metals Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • United International Enterprises Limited:企業の戦略・SWOT・財務情報
    United International Enterprises Limited - Strategy, SWOT and Corporate Finance Report Summary United International Enterprises Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT …
  • Fidelity National Financial Inc:企業の戦略・SWOT・財務情報
    Fidelity National Financial Inc - Strategy, SWOT and Corporate Finance Report Summary Fidelity National Financial Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Deutsche Biotech Innovativ AG (VUA):製薬・医療:M&Aディール及び事業提携情報
    Summary Deutsche Biotech Innovativ AG (DBI), formerly Venetus Beteiligungen AG, is a biotechnology company that develops drug candidates on indications sepsis and cancer. The company’s products comprise Adrecizumab, DB1RA and AB2302. It diagnostic based drug development approach and offers identific …
  • Optus Inc:企業の戦略的SWOT分析
    Optus Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Th …
  • Prismic Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Prismic Pharmaceuticals Inc (Prismic Pharmaceuticals) is a specialty pharmaceutical company that offers development of prescription drugs. The company offers research and development programs for prescription product candidates and provides unique safety profiles. It develops drugs for infla …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆